The Trump administration had proposed a two-step approach to expand coverage of GLP-1s for obesity in Medicare
Chronic Kidney Disease (CKD) is a health issue that affects about 37 million adults in the United States
If a product has not been FDA-approved for a specific condition, it cannot be promoted as safe or effective for that condition
We start with a comprehensive consultation, including advanced diagnostics, to understand your metabolic health and weight loss barriers
altRx GLP-1 Review 2026: Updated for the Latest FDA Compounded Semaglutide Action - Pricing, Refund Policy, and What's Changing Compounded Semaglutide and Tirzepatide Pricing from $89, How Eligibility and Self-Pay Work, and What Patients Should Verify Before Submitting Intake ALPHARETTA, Ga., May 9, 2026 (Newswire.com) - Last Updated: May 2026
These include side effects, risk of nutrient inadequacies, muscle, and bone loss, high costs, frequent discontinuation, and weight regain